Can a targeted antibody give pancreatic cancer chemo a boost?

NCT ID NCT04825288

Completed Disease control Sponsor: XBiotech, Inc. Source: ClinicalTrials.gov ↗

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This trial is testing whether adding an experimental antibody called XB2001 to a standard chemotherapy regimen can help people with advanced pancreatic cancer. The study has two parts: first, it finds the safest dose of XB2001, then it compares the antibody plus chemo against a placebo plus chemo in about 60 patients. The goal is to see if the combination can slow cancer growth and improve outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: XB2001 (anti-IL-1⍺ true human antibody) added to a chemotherapy regimen of ONIVYDE, 5-FU, and leucovorin
What this could lead to: If it works, this could point toward a new combination treatment that slows the growth of advanced pancreatic cancer.
What could go wrong: This is an early-phase trial, so the added benefit is uncertain. The antibody could also increase side effects when combined with chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Alliance for Multispecialty Research, LLC

Merriam, Kansas, 66204, United States
Arizona Oncology Associates

Tucson, Arizona, 85711, United States
Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Bon Secours St. Francis Cancer Center

Midlothian, Virginia, 23114, United States
Cleveland Clinic of Florida

Weston, Florida, 33331, United States
Community Cancer Trials of Utah

Ogden, Utah, 84405, United States
Disney Family Cancer Center at Providence St. Joseph Medical Center

Burbank, California, 91505, United States
Goshen Center for Cancer Care

Goshen, Indiana, 46526, United States
Grand Valley Oncology

Grand Junction, Colorado, 81505, United States
Hoag Memorial Hospital Presbyterian

Newport Beach, California, 92663, United States
Mary Crowley Cancer Research

Dallas, Texas, 75230, United States
Montefiore Einstein Medical Center

The Bronx, New York, 10461, United States
Mt. Sinai Comprehensive Cancer Center

Miami Beach, Florida, 33140, United States
Ochsner Clinic Foundation

New Orleans, Louisiana, 70121, United States
Providence Portland

Portland, Oregon, 97213, United States
Providence St. Joseph Heritage - Fullerton, CA

Fullerton, California, 92835, United States
Revive Research - Farmington Hills

Farmington Hills, Michigan, 48334, United States
Revive Research - Sterling Heights

Sterling Heights, Michigan, 48126, United States
Sarah Cannon - Florida Cancer Specialists

Lake Mary, Florida, 32746, United States
Sarah Cannon - Tennessee Oncology

Nashville, Tennessee, 37203, United States
Sarasota Memorial Hospital

Sarasota, Florida, 34239, United States
St. Vincent Frontier Cancer Center

Billings, Montana, 59102, United States
Stony Brook Cancer Center

Stony Brook, New York, 11794, United States
Summit Medical Group

Florham Park, New Jersey, 07932, United States
TOI Clinical Research

Cerritos, California, 90703, United States
Texas Oncology - Arlington

Arlington, Texas, 76012, United States
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
University of Tennessee Medical Center Cancer Institute

Knoxville, Tennessee, 37920, United States
Vanderbilt University

Nashville, Tennessee, 37232, United States
Virginia Cancer Specialists

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.